Sugi Predict

Sugi Predict / Compounds / SCHEMBL739765

SCHEMBL739765

SCHEMBL739765

COC1CCN(C(=O)C(C)C)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 1/20 0.44
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNA3 P32297 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43
▸ CHRNB3 Q05901 1/20 0.43
▸ CHRNA6 Q15825 1/20 0.43
▸ PDE9A O76083 1/20 0.41
▸ PDE1B Q01064 1/20 0.41
▸ NAMPT P43490 1/20 0.40
▸ DPP4 P27487 6/20 0.39
▸ DPP7 Q9UHL4 2/20 0.39
▸ VNN1 O95497 2/20 0.38
▸ PIK3CD O00329 3/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ DPP8 Q6V1X1 2/20 0.37
▸ DPP9 Q86TI2 2/20 0.37
▸ NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22000200 1.00 PDE4B (0.44) PDE4BCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL27405335 1.00 PDE4B (0.44) PDE4BCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL738191 0.89 KMT2A (0.44) PDE4BCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL17308198 0.87 PDE9A (0.40) PDE4BPDE9APDE1BDPP4DPP7
SCHEMBL16132288 0.87 PDE9A (0.40) PDE4BPDE9APDE1BDPP4DPP7
SCHEMBL12521657 0.87 PDE9A (0.40) PDE4BPDE9APDE1BDPP4DPP7
SCHEMBL17308197 0.87 PDE9A (0.40) PDE4BPDE9APDE1BDPP4DPP7
SCHEMBL17308204 0.87 PDE9A (0.40) PDE4BPDE9APDE1BDPP4DPP7
SCHEMBL12521649 0.87 PDE9A (0.40) PDE4BPDE9APDE1BDPP4DPP7
SCHEMBL15045183 0.86 DPP4 (0.43) PDE9APDE1BDPP4DPP7DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF DICE MOLECULES SV, INC. 2024-06-27 — — US disclosed
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF DICE MOLECULES SV, INC. 2024-06-27 — — US disclosed
US-11834433-B2 Compounds INFLAZOME LIMITED (IE) 2023-12-05 — — US disclosed
WO-2022111473-A1 COMPOUNDS AS MRGPRX2 ANTAGONISTS BIOARDIS LLC (US) 2022-06-02 — — WO disclosed
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein PRELUDE THERAPEUTICS, INCORPORATED (US) 2021-09-28 — — US disclosed
US-20210122739-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2021-04-29 — — US disclosed
US-20210040065-A1 NOVEL COMPOUNDS INFLAZOME LIMITED (IE) 2021-02-11 — — US disclosed
US-20200317637-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-10-08 — — US disclosed
US-20200148705-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein PRELUDE THERAPEUTICS, INCORPORATED 2020-05-14 — — US disclosed
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 — — US disclosed
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 — — US disclosed
US-8138181-B2 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-03-20 — — US disclosed
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-06-10 — — US disclosed
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF ITGB1, ITGA1, ITGAV PDE4B 1596/4885CHRNB2 341/4885CHRNA3 284/4885
US-20100029633-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 PDE4B 2033/4885CHRNB2 3290/4885CHRNA3 1958/4885
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 PDE4B 3351/4885CHRNB2 4198/4885CHRNA3 2918/4885
US-20210040065-A1 NOVEL COMPOUNDS NLRP3, NOD1, NLRP1 PDE4B 1429/4885CHRNB2 4640/4885CHRNA3 4451/4885
US-20210122739-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, PYCARD, NOD1 PDE4B 1304/4885CHRNB2 4611/4885CHRNA3 4304/4885
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein MCL1, BCL2A1, BCL2L1 PDE4B 4568/4885CHRNB2 4868/4885CHRNA3 4866/4885
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PDE4B 403/4885CHRNB2 3477/4885CHRNA3 3362/4885
US-20200317637-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, PYCARD PDE4B 1617/4885CHRNB2 4441/4885CHRNA3 4073/4885
US-11834433-B2 Compounds NLRP3, NOD1, PYCARD PDE4B 1811/4885CHRNB2 4742/4885CHRNA3 4566/4885
US-20200148705-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein MCL1, BCL2A1, BCL2L1 PDE4B 4568/4885CHRNB2 4868/4885CHRNA3 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.